title: The role of the cytokines in the pathogenesis of pseudoexfoliation syndrome.
abstract: OBJECTIVE
  To examine the mechanism of the development of pseudoexfoliation (PSX) syndrome via both cytokine formation and endothelial vasorelaxing and growth factors that will provide us new therapeutic insights for the treatment.
  
  
  METHODS
  This is a cross sectional study included two groups; Group 1: control patients with nuclear cataract (n=20, aged 51-80 years). Group 2: PSX patients with nuclear cataract (n=18, aged 50-90 years). Patients with other ophthalmic problems and systemic diseases were excluded. Vascular endothelial growth factor (VEGF), interleukin-6 (IL-6) and interleukin-1β (IL-1β) and nitrotyrosine levels were determined through serum samples by Enzyme-linked immunosorbent assay (ELISA) method. Nitrite-nitrate levels were measured with photometric endpoint determination.
  
  
  RESULTS
  There were no significant differences between the groups in terms of age, VEGF, IL-1β, nitrite-nitrate and nitrotyrosine. The significant results were the mean IL-6 levels that were higher in PSX group 2 (37.68±29.52 pg/mL) compared to that in control group 1 (15.32±10.08 pg/mL) (P<0.001).
  
  
  CONCLUSIONS
  Several interacting and extending biochemical pathways may lead to the promotion of VEGF and IL-6 expressions. IL-6 which is the only altered marker in our study may indirectly cause an increase of vascular permeability and neovascularization. We suggest inflammation as a factor that can be involved in etiopathogenesis of PSX.
authors.affiliation: Etimesgut Public Health Laboratory, Etimesgut 06770, Ankara, Turkey.
authors.forename: Zuhal
authors.initials: Z
authors.lastname: Yildirim
authors.forename: Filiz
authors.initials: F
authors.lastname: Yildirim
authors.forename: Nil Irem
authors.initials: NI
authors.lastname: Uçgun
authors.forename: Aylin
authors.initials: A
authors.lastname: Sepici-Dinçel
keywords: inflammation; interleukin-1β; interleukin-6; pseudoexfoliation syndrome; vascular endothelial growth factor
references.citation: Ophthalmologe. 2012 Oct;109(10):944-51
references.pmid: 23053330
references.citation: Eye (Lond). 2008 Jan;22(1):128-31
references.pmid: 17293783
references.citation: Ophthalmology. 2003 Sep;110(9):1690-6
references.pmid: 13129863
references.citation: J Ocul Pharmacol Ther. 2001 Apr;17(2):189-98
references.pmid: 11324986
references.citation: Am J Ophthalmol. 2006 May;141(5):921-937
references.pmid: 16678509
references.citation: Eur J Ophthalmol. 1993 Apr-Jun;3(2):95-7
references.pmid: 8353437
references.citation: Horm Metab Res. 2001 May;33(5):317-22
references.pmid: 11440280
references.citation: Ophthalmology. 1995 Jan;102(1):108-17
references.pmid: 7831024
references.citation: Ophthalmology. 2000 Aug;107(8):1588-92
references.pmid: 10919914
references.citation: Graefes Arch Clin Exp Ophthalmol. 2005 Jul;243(7):677-83
references.pmid: 15688159
references.citation: Clin Chem. 1995 Jun;41(6 Pt 1):904-7
references.pmid: 7768010
references.citation: Br J Ophthalmol. 2007 Jan;91(1):29-32
references.pmid: 16943231
references.citation: Acta Ophthalmol Scand. 2002 Apr;80(2):191-5
references.pmid: 11952488
references.citation: Nitric Oxide. 2001 Feb;5(1):62-71
references.pmid: 11178938
references.citation: Ophthalmologe. 2012 Oct;109(10):942-3
references.pmid: 23053329
references.citation: Ophthalmology. 2004 Dec;111(12):2186-92
references.pmid: 15582072
references.citation: Acta Ophthalmol Scand. 2004 Feb;82(1):49-53
references.pmid: 14982047
references.citation: J Glaucoma. 2010 Mar;19(3):207-11
references.pmid: 19593200
references.citation: Am J Ophthalmol. 2005 Jan;139(1):72-7
references.pmid: 15652830
references.citation: J Biol Chem. 1996 Jan 12;271(2):736-41
references.pmid: 8557680
references.citation: Surv Ophthalmol. 2001 Jan-Feb;45(4):265-315
references.pmid: 11166342
references.citation: Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):241-7
references.pmid: 22159018
references.citation: Ophthalmologe. 2012 Oct;109(10):952-61
references.pmid: 23053333
references.citation: J Clin Invest. 1997 Jun 1;99(11):2625-34
references.pmid: 9169492